Skip to main content
Clinical Trials/NCT05115266
NCT05115266
Not Yet Recruiting
N/A

Efficacy of Animal-assisted Therapy in Patients With Borderline Personality Disorder and Addictions.

Miguel Monfort Montolio0 sites200 target enrollmentApril 30, 2022

Overview

Phase
N/A
Intervention
Not specified
Conditions
Diagnosis, Dual (Psychiatry)
Sponsor
Miguel Monfort Montolio
Enrollment
200
Primary Endpoint
Calgary Depresión Scale for Schizophrenia (CDSS)
Status
Not Yet Recruiting
Last Updated
4 years ago

Overview

Brief Summary

Animal-assisted therapy (AAT) is a complementary intervention of therapy that has shown positive results in the treatment of various pathologies. This study assesses the viability of the implementation and the effectiveness of an AAT program in patients diagnosed with borderline personality disorder and substance abuse disorder.

Our hypotheses are that participation in the TAA program will reduce negative symptoms, improve the quality of life of people with dual pathology, whose mental illness is schizophrenia, and increase adherence to treatment for people with dual pathology, whose mental disorder it's schizophrenia.

Detailed Description

Animal assisted therapy (AAT) is a complementary intervention to therapy that presents positive results in the treatment of different pathologies. The study assesses the implementation and effectiveness of a TAA program in patients diagnosed with borderline personality disorder and substance abuse disorder.

Registry
clinicaltrials.gov
Start Date
April 30, 2022
End Date
April 30, 2025
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Miguel Monfort Montolio
Responsible Party
Sponsor Investigator
Principal Investigator

Miguel Monfort Montolio

Miguel Monfort Montolio, member of the TXP research group at Cardenal Herrera University

Cardenal Herrera University

Eligibility Criteria

Inclusion Criteria

  • Meeting DSM-5 criteria for substance abuse disorder and the presence of borderline personality disorder.
  • Voluntary participant in the study and having signed the informed consent

Exclusion Criteria

  • Patients whose functioning could be altered by factors not specifically related to addictive pathology or mental disorder (severe cognitive impairment, intellectual deficiency or language barrier)
  • Animal-specific phobia

Outcomes

Primary Outcomes

Calgary Depresión Scale for Schizophrenia (CDSS)

Time Frame: Change from Depresión at 3-6-9 months (12 minutes)

The questionnaire is a structured instrument, administered by a clinician in a hetero-applied way for the adult population, with an approximate administration time of between 10 and 30 minutes, and covers the therapeutic area related to the symptoms of depressive disorders.

Positive and negative symptom scale (PANSS)

Time Frame: Change from Positive and negative symptom at 3-6-9 months (12 minutes)

It is a semi-structured and hetero-applied questionnaire for the adult population. The application time is between 30-60 minutes and evaluates the positive and negative symptoms of schizophrenia and other psychotic disorders

Rosenberg Self-Esteem Scale

Time Frame: Change from self-esteem at 3-6-9 months (12 minutes)

The questionnaire consists of 10 statements of the feelings that the person has about himself. Five of the statements are addressed positively (items 1, 2, 4, 6 and 7) and 5 negatively (items 3, 5, 8, 9 and 10).

The Life Skills Profile questionnaire (LSP)

Time Frame: Change from Life Skills at 3-6-9 months (12 minutes)

This questionnaire evaluates aspects of functioning that affect daily activities and the adaptation of people with mental illnesses in the community. It contains 39 items that are grouped into self-care, social-interpersonal behaviour, communication-social contact, non-personal social behavior and autonomous life

Barrat impulsiveness scale (BIS-11)

Time Frame: Change from impulsiveness at 3-6-9 months (12 minutes)

This instrument is composed of 30 items distributed into three sub-scales: nonplanning, motor and attentional. The total impulsiveness score was also obtained

Similar Trials